SAN FRANCISCO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the Canaccord Genuity 43^rd Annual Growth Conference in Boston on Wednesday, August 9, 2023, at 2:00 p.m. ET.

A live webcast of the Fireside Chat and any accompanying presentation materials will be available under the News & Events section of Olema’s investor relations website at www.olema.com. The webcast will be archived for at least 30 days. 

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

IR Contact:
Shane Kovacs, Chief Operating and Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
This email address is being protected from spambots. You need JavaScript enabled to view it.